COVID-19 Vaccine Should Demonstrate At Least 50% Effectiveness, US FDA Says
Executive Summary
Guidance on COVID-19 vaccine development and licensure appears to set a precedent in specifying the clinical efficacy rate for a product approval; agency also takes accelerated approval off the table for now and says emergency use authorization may be granted only after safety and efficacy have been demonstrated.
You may also be interested in...
After EUA, COVID Vaccine Sponsors Need Plans For Continuing Trials
EUA request should also include plan for a sponsor’s active follow-up for safety among individuals given the vaccine under EUA – including assessing deaths, hospitalizations and other clinically significant adverse events – to inform ongoing benefit-risk determinations to support the continued authorization, US FDA says in its finally-released guidance.
Transparency, And A Mirror: US FDA Advice On COVID-19 Vaccine EUAs Finally Published – Twice
Everyone but Donald Trump seems happy that the guidance is finally here, with release appearing to be driven by FDA's disclosure of advisory committee materials.
One Goal, Four Paths: Comparing COVID-19 Vaccine Pivotal Trial Protocols
Phase III protocols for COVID-19 vaccine candidates from Pfizer/BioNTech, Moderna, AstraZeneca and Johnson & Johnson are similar – but definitely not the same.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: